e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Acute respiratory failure
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhalation of activated recombinant factor VII to treat pulmonary hemorrhage in a patient with cystic fibrosis
C. Marcu, R. Bals, A. Groeschel, C. Lensch, J. Woerner, S. Faendrich (Homburg, Germany)
Source:
Annual Congress 2011 - Acute respiratory failure
Session:
Acute respiratory failure
Session type:
Thematic Poster Session
Number:
2041
Disease area:
Respiratory critical care
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Marcu, R. Bals, A. Groeschel, C. Lensch, J. Woerner, S. Faendrich (Homburg, Germany). Inhalation of activated recombinant factor VII to treat pulmonary hemorrhage in a patient with cystic fibrosis. Eur Respir J 2011; 38: Suppl. 55, 2041
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Related content which might interest you:
The protease activated receptor (PAR)-2/tissue factor/coagulation factor VIIa axis in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Source: Eur Respir J 2007; 29: 240-250
Year: 2007
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Coagulation and anticoagulation in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 392-399
Year: 2015
Inhalation therapy in cystic fibrosis
Source: School Course 2013 - Cystic Fibrosis
Year: 2013
Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 266s
Year: 2005
Massive hemoptysis in cystic fibrosis adult patients
Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health
Year: 2008
LATE-BREAKING ABSTRACT: Coagulation factor IX deficiency does not afford protection from pulmonary fibrosis in the experimental murine bleomycin model
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Predictive factors for severe pulmonary exacerbations in patients with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 715s
Year: 2006
Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017
Year: 2018
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1393-1402
Year: 2015
Aetiology of non cystic fibrosis bronchiectasis and its correlation with the site of pulmonary damage
Source: Eur Respir J 2003; 22: Suppl. 45, 504s
Year: 2003
Pulmonary hypertension in cystic fibrosis patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
Source: Eur Respir J, 49 (5) 1700178; 10.1183/13993003.00178-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept